According to statistics, in 2016, China's medical and health industry market was close to 3 trillion yuan. According to research data from Stanford University, the market size of China's health industry will reach 8 trillion yuan in 2020. What kind of concept is 8 trillion? Such a huge number means that this is a “great gold mine†that will never be ignored by people in capital markets such as VC/PE and listed companies. The medical industry, which has always been called “absolutely sullen and richâ€, seems to be no longer immersed in the low-key of the past in 2017. 2017, the overseas medical mergers and acquisitions of listed companies have come On the evening of May 4, the listed company Hengkang Medical announced that its Australian wholly-owned subsidiary, Hengkang Medical Investment, intends to acquire 70% of PRP's shares for approximately 1.694 billion yuan. According to the announcement, PRP is Australia's second largest professional imaging diagnostic company. As of December 31, 2016, PRP has 29 imaging diagnostic centers in New South Wales, Australia, providing diagnostic imaging services to patients. The company achieved revenue of 825 million yuan in fiscal year 2016 and net profit of 184 million yuan. In addition, following the acquisition, the equity cooperation between Hengkang Medical and the top three hospitals is also involved. According to the announcement of Hengkang Medical, the company and related parties have made significant progress on the equity cooperation of a large-scale top three hospital in China, and intend to sign a major strategic agreement on equity cooperation with relevant parties. According to the information of Hengkang Medical's official website, Hengkang Medical was established in 2001. On March 6, 2008, it was listed on the SME Board of Shenzhen Stock Exchange. It is a comprehensive modernization group that focuses on medical, pharmaceutical, daily chemical and health care. the company. In fact, this is not the case of this year's first listed company to acquire medical companies overseas. The author once reported on May 2, 2017 that the listed company Chutian Technology and its controlling shareholder Changsha Chutian Investment Co., Ltd. (Chutian Investment) and Yi Investment invested on April 28, 2017 at a price of RMB 1.1 billion. Acquired a 75.1% stake in the German pharmaceutical company Romaco Group. Founded in 2000, Chutian Technology is the main business of providing intelligent medical equipment solutions for the market, and is the first to promote the research and development of smart pharmaceutical factories. The company owns a number of wholly-owned or holding subsidiaries such as Chutian Huatong, Sichuan Pharmaceutical Design Institute and Chutian Intelligent Robot. On January 21, 2014, it landed on the GEM of the Shenzhen Stock Exchange. On April 11, the listed company Aier Ophthalmology issued a major announcement, and the company intends to hold ClÃnica Baviera, S. through indirect wholly-owned Aier International (Europe) Co., Ltd. A. Shareholders of 100% of the shares initiated a voluntary offer, with a purchase price of 152 million euros. In addition, in January 2017, China's privately-owned three-unit group announced the acquisition of 100% of the US biopharmaceutical company Dendreon Pharmaceuticals for $819 million in cash. It is understood that this acquisition also sets the largest transaction record for Chinese companies to acquire US drugs. Yu Mingde, the former president of the China Pharmaceutical Enterprise Management Association, has analyzed externally. Overseas mergers and acquisitions are the inevitable result of the development of Chinese enterprises. On the one hand, China's reform and opening up to this day, domestic enterprises have already had "equal accumulation", and will inevitably seek to develop themselves with global resources, use funds to buy innovative drugs or advanced technologies, and use the ready-made brands, markets and channels of the target companies. Faster development. On the other hand, while acquiring overseas companies, it has also achieved “localization†in the target market. Therefore, domestic companies participating in overseas mergers and acquisitions will be a general direction in the future. In addition, it is interesting to note that the three listed companies mentioned above are listed on the Shenzhen Stock Exchange. Herbal Extract,Eupatorium Extract Powder,Eupatorium Adenophorum Extract Powder,Eupatorium Perfoliatum Extract Powder Fufeng Sinuote Biotechnology Co.,Ltd. , https://www.sntbiology.com